IL-15 DC

News alerts, weekly reports and conference planners

Company:

Baylor University

Drug class:

CD8 T-cell agonist

Related drugs:

almost3years

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. (PubMed, Front Immunol)

Ultimately designed to induce a durable tumor antigen-specific immune response, PD-L silenced IL-15 DCs were capable of surpassing PD-1-mediated inhibition by antigen-specific T cells. Further corroborating the superior potency of short-term IL-15 DCs, the combination of immune stimulatory components during DC differentiation and maturation with in situ checkpoint inhibition supports further clinical translation.

almost 3 years ago

Journal

PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • PD-L2 (Programmed Cell Death 1 Ligand 2)

IL-15 DC